Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Asset Writedowns and Impairment data on file, last reported at $111000.0 in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 141.3% year-over-year to $111000.0 in Q1 2026; TTM through Mar 2026 was $694000.0, a 24.24% decrease from a year earlier, with the FY2025 full-year figure at $629000.0, up 222.56% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $111000.0, up from -$4.3 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for ANIK reached as high as $62.2 million in Q4 2023 and fell as low as -$4.3 million in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $4.5 million across 5 years, with a median of $607500.0 in 2022.
• Across the five-year window, Asset Writedowns and Impairment tumbled 190.0% in 2022 and soared 3720.02% in 2023, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $1.6 million in 2022, then surged by 3720.02% to $62.2 million in 2023, then sank by 104.67% to -$2.9 million in 2024, then slumped by 49.35% to -$4.3 million in 2025, then soared by 102.56% to $111000.0 in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $111000.0 in Q1 2026, -$4.3 million in Q4 2025, and $4.7 million in Q3 2025.